International Journal of Clinical Case Reports 2024, Vol.14, No.4 http://medscipublisher.com/index.php/ijccr © 2024 MedSci Publisher, registered at the publishing platform that is operated by Sophia Publishing Group, founded in British Columbia of Canada. All Rights Reserved. Publisher
International Journal of Clinical Case Reports 2024, Vol.14, No.4 http://medscipublisher.com/index.php/ijccr © 2024 MedSci Publisher, registered at the publishing platform that is operated by Sophia Publishing Group, founded in British Columbia of Canada. All Rights Reserved. MedSci Publisher is an international Open Access publisher specializing in clinical case, clinical medicine, new variations in disease processesregistered at the publishing platform that is operated by Sophia Publishing Group (SPG), founded in British Columbia of Canada. Publisher MedSci Publisher Editedby Editorial Team of International Journal of Clinical Case Reports Email: edit@ijccr.medscipublisher.com Website: http://medscipublisher.com/index.php/ijccr Address: 11388 Stevenston Hwy, PO Box 96016, Richmond, V7A 5J5, British Columbia Canada International Journal of Clinical Case Reports (ISSN 1927-579X) is an open access, peer reviewed journal published online by MedSci Publisher. The journal is considering all the latest and outstanding research articles, letters and reviews in all aspects of clinical case, containing clinical medicine which advance general medical knowledge; the event in the course of observing or treating a patient; new variations in disease processes; as well as the expands the field of clinical relating to case reports. All the articles published in International Journal of Clinical Case Reports are Open Access, and are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. MedSci Publisher uses CrossCheck service to identify academic plagiarism through the world’s leading plagiarism prevention tool, iParadigms, and to protect the original authors’ copyrights.
International Journal of Clinical Case Reports (online), 2024, Vol. 14, No.4 ISSN 1927-579X http://medscipublisher.com/index.php/ijccr © 2024 MedSci Publisher, registered at the publishing platform that is operated by Sophia Publishing Group, founded in British Columbia of Canada. All Rights Reserved. Latest Content Management of Diabetes Complications Based on Clinical Cases: Current Status and Prospects Shanshan Shi, Yongkang Huang, Qi Wang, Jiang Zhu International Journal of Clinical Case Reports, 2024, Vol. 14, No. 4, 175-188 Immune Checkpoint Blockade in Renal Cell Carcinoma: Therapeutic Efficacy and Mechanisms of Resistance ManmanLi International Journal of Clinical Case Reports, 2024, Vol. 14, No. 4, 189-201 Genetic Analysis and Clinical Application of HOXB13 Variants in Prostate Cancer Jianmin Wang International Journal of Clinical Case Reports, 2024, Vol. 14, No. 4, 202-209 Review of Classic Cases in Long-term Management of Chronic Obstructive Pulmonary Disease YaoguoSun International Journal of Clinical Case Reports, 2024, Vol. 14, No. 4, 210-220 Advancements in Gastric Cancer Resection Techniques: Current Status and Future Directions MingZhang International Journal of Clinical Case Reports, 2024, Vol. 14, No. 4, 221-229
International Journal of Clinical Case Reports 2024, Vol.14, No.4, 175-188 http://medscipublisher.com/index.php/ijccr 175 Review Article Open Access Management of Diabetes Complications Based on Clinical Cases: Current Status and Prospects Shanshan Shi *, Yongkang Huang*, Qi Wang, Jiang Zhu College of Medical Informatics, Daqing Campus of Harbin Medical University, Daqing, 163000, Heilongjiang, China Corresponding author: hydzhujiang@126.com * These authors contributed equally to this work International Journal of Clinical Case Reports 2024, Vol.14, No.4 doi: 10.5376/ijccr.2024.14.0019 Received: 16 May, 2024 Accepted: 20 Jun., 2024 Published: 06 Jul., 2024 Copyright © 2024 Shi et al., This is an open access article published under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Preferred citation for this article: Shi S.S., Huang Y.K., Wang Q., and Zhu J., 2024, Management of diabetes complications based on clinical cases: current status and prospects, International Journal of Clinical Case Reports, 14(4): 175-188 (doi: 10.5376/ijccr.2024.14.0019) Abstract The management of diabetes complications remains a critical aspect of diabetes care, necessitating a comprehensive understanding of current practices and future prospects. This study synthesizes findings from various clinical cases to evaluate the current status and potential advancements in managing diabetes complications; highlights the importance of multidisciplinary approaches, technological innovations, and personalized treatment strategies in improving patient outcomes. Key areas of focus include the integration of diabetes technologies such as continuous glucose monitoring and insulin pump therapy, the role of self-management education, and the impact of social determinants of health on diabetes care. The findings underscore the need for ongoing research and the development of tailored interventions to address the diverse needs of diabetes patients, ultimately aiming to reduce the burden of diabetes complications and enhance quality of life. Keywords Diabetes management; Complications; Technology; Self-management; Personalized treatment 1 Introduction Breast cancer is the most commonly diagnosed cancer among women worldwide and remains a leading cause of cancer-related deaths (Basu et al., 2019; García-Aranda and Redondo, 2019; Hu et al., 2023). In 2020 alone, there were an estimated 2.3 million new cases and 685 000 deaths attributed to breast cancer globally (Luo et al., 2022). Historically, the treatment of breast cancer has relied heavily on surgery, radiation, and systemic therapies such as chemotherapy and hormone therapy. These conventional treatments have significantly improved patient outcomes, yet challenges such as tumor heterogeneity, treatment resistance, and disease recurrence persist (Basu et al., 2019; Venetis et al., 2020). Effective management of diabetes is crucial not only for controlling blood glucose levels but also for preventing the myriad complications associated with the disease. Chronic hyperglycemia can lead to both microvascular and macrovascular complications, including diabetic retinopathy, nephropathy, neuropathy, cardiovascular diseases, and stroke (Laddha et al., 2019; Paul et al., 2020). These complications significantly contribute to the high morbidity and mortality rates observed among patients with diabetes. Moreover, the economic burden of managing diabetes and its complications is substantial, further emphasizing the need for effective therapeutic strategies (Tan et al., 2019; Paul et al., 2020). Various therapeutic approaches, including pharmacological interventions, lifestyle modifications, and novel drug delivery systems, have been explored to mitigate these complications and improve patient outcomes (Jud and Sourij, 2019; Zhao et al., 2020). This study provides a comprehensive overview of the current status and future prospects in the management of diabetes complications based on clinical cases; synthesizes the latest research findings on the pathophysiology of diabetes complications, the molecular mechanisms involved, and the therapeutic strategies employed to manage these complications. By examining clinical case studies, this study highlights the practical applications of these therapeutic approaches and identifies potential areas for future research. The scope includes an analysis of conventional and emerging treatments, the role of natural products and dietary
International Journal of Clinical Case Reports 2024, Vol.14, No.4, 175-188 http://medscipublisher.com/index.php/ijccr 176 interventions, and the development of advanced drug delivery systems to enhance the efficacy and safety of diabetes management. 2 Overview of Diabetes Complications 2.1 Classification of complications: microvascular and macrovascular Diabetes complications are broadly classified into two categories: microvascular and macrovascular. Microvascular complications include diabetic retinopathy, nephropathy, and neuropathy, which are primarily caused by damage to small blood vessels due to chronic hyperglycemia (Holt, 2018; Paul et al., 2020; Crasto et al., 2021). On the other hand, macrovascular complications involve larger blood vessels and include cardiovascular diseases such as coronary artery disease, stroke, and peripheral arterial disease (Yamazaki et al., 2018; Paul et al., 2020; Zakir et al., 2023). Both types of complications significantly contribute to morbidity and mortality in diabetic patients. 2.2 Common complications: neuropathy, nephropathy, retinopathy, cardiovascular diseases, and others Diabetic neuropathy affects the nerves and can manifest as somatic or autonomic neuropathy, leading to symptoms such as pain, tingling, and loss of sensation, particularly in the extremities. Diabetic nephropathy, characterized by kidney damage, is a leading cause of end-stage renal disease and is often indicated by the presence of albuminuria (Holt, 2018; Graves and Donaghue, 2019; Crasto et al., 2021). Diabetic retinopathy, a major cause of blindness, results from damage to the retinal blood vessels and can progress to proliferative stages if not managed effectively (Holt, 2018; Pearce et al., 2018; Graves and Donaghue, 2019; Crasto et al., 2021). Cardiovascular diseases are a significant concern in diabetic patients, encompassing coronary artery disease, stroke, and peripheral arterial disease. These conditions are exacerbated by the presence of diabetes and are linked to both microvascular and macrovascular damage (Pearce et al., 2018; Avogaro and Fadini, 2019; Paul et al., 2020; Zakir et al., 2023). Other complications include diabetic foot ulcers, which can lead to severe infections and amputations, and hypertension, which often coexists with diabetes and accelerates the progression of both microvascular and macrovascular complications (Holt, 2018; Yamazaki et al., 2018; Graves and Donaghue, 2019). 2.3 Pathophysiology of diabetes complications The pathophysiology of diabetes complications is complex and multifactorial. Chronic hyperglycemia plays a central role by inducing various biochemical pathways that lead to vascular damage. In microvascular complications, hyperglycemia activates the polyol pathway, protein kinase C pathway, advanced glycation end products (AGE) pathway, and hexosamine pathway, contributing to oxidative stress and endothelial dysfunction (Avogaro and Fadini, 2019; Paul et al., 2020). These pathways result in the overproduction of reactive oxygen species, dysregulation of growth factors and cytokines, and epigenetic changes, ultimately causing damage to small blood vessels (Paul et al., 2020). Macrovascular complications are primarily driven by atherosclerosis, a process accelerated by hyperglycemia, hypertension, and dyslipidemia. Endothelial dysfunction, chronic inflammation, and immune system dysregulation are key mechanisms linking diabetes to cardiovascular diseases (Yamazaki et al., 2018; Paul et al., 2020; Zakir et al., 2023). The interplay between microvascular and macrovascular complications suggests a continuum of vascular damage, where microvascular disease can predict and exacerbate macrovascular outcomes (Pearce et al., 2018; Avogaro and Fadini, 2019; Garofolo et al., 2019). In summary, the management of diabetes complications requires a comprehensive approach that addresses both microvascular and macrovascular risks through optimal glycemic control, blood pressure management, and lifestyle modifications (Holt, 2018; Paul et al., 2020; Crasto et al., 2021; Zakir et al., 2023). Early detection and intervention are crucial to mitigate the long-term impact of these complications on patients' health and quality of life.
International Journal of Clinical Case Reports 2024, Vol.14, No.4, 175-188 http://medscipublisher.com/index.php/ijccr 177 3 Current Management Strategies 3.1 Medical interventions 3.1.1 Pharmacological treatments Pharmacological treatments for diabetes primarily aim to control blood glucose levels and prevent complications. Various classes of antidiabetic drugs are available, including metformin, sulfonylureas, DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors. Studies have shown that specific GLP-1 receptor agonists and SGLT-2 inhibitors not only improve glycemic control but also reduce cardiovascular events in patients with type 2 diabetes (Tsapas et al., 2020). Additionally, pharmacist-led interventions have demonstrated efficacy in enhancing medication adherence, which is crucial for achieving optimal treatment outcomes (Presley et al., 2019). 3.1.2 Insulin therapy and advancements Insulin therapy remains a cornerstone for managing diabetes, especially in patients with advanced disease or those who do not respond adequately to oral medications. Intravenous insulin therapy is particularly effective in critical care settings. Recent advancements in diabetes technology, such as continuous glucose monitoring and automated insulin delivery systems, are revolutionizing insulin therapy by providing more precise and individualized treatment options (Pasquel et al., 2021). Moreover, targeted insulin-adherence interventions using predictive analytics have shown promise in improving glycemic control among patients with type 2 diabetes (Lauffenburger et al., 2019). 3.1.3 Role of antidiabetic medications in managing complications Antidiabetic medications play a significant role in managing both microvascular and macrovascular complications of diabetes. Multifactorial interventions that include pharmacotherapy for associated risk factors, such as hypertension and dyslipidemia, alongside glycemic control, have been shown to reduce cardiovascular and renal events (Sasako et al., 2023). Additionally, adherence to antidiabetic and cardiovascular drugs is crucial for preventing renal and cardiovascular complications, as non-adherence is associated with worse outcomes (Denicolò et al., 2021). 3.2 Non-Medical interventions 3.2.1 Lifestyle modifications: diet, exercise, and weight management Lifestyle modifications, including diet, exercise, and weight management, are fundamental components of diabetes management. Structured weight-management programs have demonstrated significant benefits, including the remission of type 2 diabetes in a substantial proportion of patients (Lean et al., 2019). Non-pharmacological interventions, such as nutritional therapy and physical activity, are effective in glycemic control and are often recommended as first-line treatments (Leite et al., 2020; Yin et al., 2022). 3.2.2 Monitoring and early detection Regular monitoring and early detection of diabetes-related complications are essential for effective management. Self-blood glucose monitoring and continuous glucose monitoring systems help patients maintain optimal glycemic control and detect fluctuations in blood glucose levels (Pasquel et al., 2021). Early detection of complications through routine screenings can lead to timely interventions and better outcomes. 3.2.3 Role of patient education and self-management Patient education and self-management are critical for the successful management of diabetes. Diabetes self-management education and support (DSMES) programs have been shown to improve glycemic control, enhance quality of life, and reduce the risk of complications (Leite et al., 2020). Pharmacist-led educational interventions also play a significant role in improving medication adherence and overall diabetes management (Presley et al., 2019). Effective patient education empowers individuals to take an active role in their care, leading to better health outcomes.
International Journal of Clinical Case Reports 2024, Vol.14, No.4, 175-188 http://medscipublisher.com/index.php/ijccr 178 4 Clinical Case Studies: Current Practices 4.1 Case study 1: management of diabetic neuropathy 4.1.1 Patient background and diagnosis A 55-year-old male patient with a 10-year history of type 2 diabetes mellitus presented with symptoms of numbness, tingling, and burning pain in his lower extremities. The patient reported that the pain was particularly severe at night, affecting his sleep quality. Physical examination revealed decreased sensation in a stocking-glove distribution, and nerve conduction studies confirmed the diagnosis of distal symmetric polyneuropathy, a common form of diabetic neuropathy (Figure 1) (Feldman et al., 2019; Saraswat et al., 2023). 4.1.2 Treatment approach and outcomes The treatment plan included optimizing glycemic control, initiating pregabalin for neuropathic pain, and recommending lifestyle modifications such as regular exercise and smoking cessation. The patient was also referred to a psychologist for cognitive-behavioral therapy to address anxiety and depression associated with chronic pain (Kioskli et al., 2019; Braffett et al., 2020). After six months, the patient reported significant pain relief and improved sleep quality, although some sensory deficits persisted (Shin et al., 2018; Jensen et al., 2021). 4.2 Case study 2: management of diabetic nephropathy 4.2.1 Patient background and diagnosis A 60-year-old female patient with a 15-year history of type 2 diabetes mellitus and hypertension presented with persistent proteinuria and elevated serum creatinine levels. The patient had a history of poor glycemic control, with HbA1c levels consistently above 8%. A kidney biopsy confirmed the diagnosis of diabetic nephropathy (Sasso et al., 2021; Carvajal-Moreno et al., 2022). 4.2.2 Treatment approach and outcomes The treatment strategy involved intensive multifactorial intervention, including strict blood pressure control with ACE inhibitors, improved glycemic control targeting an HbA1c of less than 7%, and lipid-lowering therapy. The patient was also advised to follow a low-protein diet to reduce kidney workload (Xu et al., 2020; Sasso et al., 2021). Over a follow-up period of two years, the patient showed stabilization of kidney function and a reduction in proteinuria, although complete remission was not achieved (Sasso et al., 2021). 4.3 Case study 3: management of diabetic retinopathy 4.3.1 Patient background and diagnosis A 50-year-old male patient with a 12-year history of type 1 diabetes mellitus presented with blurred vision and floaters. Fundoscopic examination revealed multiple microaneurysms, hemorrhages, and neovascularization, consistent with proliferative diabetic retinopathy (Xu et al., 2020). 4.3.2 Treatment approach and outcomes The patient underwent panretinal photocoagulation therapy to prevent further progression of retinopathy. Additionally, intravitreal injections of anti-VEGF agents were administered to reduce macular edema. The patient was also counseled on the importance of maintaining optimal glycemic control and regular ophthalmologic follow-ups. After one year, the patient experienced stabilization of vision and no further progression of retinopathy (Xu et al., 2020). 4.4 Case study 4: management of cardiovascular complications 4.4.1 Patient background and diagnosis A 65-year-old male with a 20-year history of type 2 diabetes mellitus and a previous of myocardial infarction presented with chest pain and shortness of breath. Cardiac evaluation revealed significant coronary artery disease, and the patient was diagnosed with diabetic cardiovascular autonomic neuropathy (Braffett et al., 2020).
International Journal of Clinical Case Reports 2024, Vol.14, No.4, 175-188 http://medscipublisher.com/index.php/ijccr 179 Figure 1 Central and peripheral mechanisms contributing to neuropathic pain in diabetic neuropathy (Adopted from Feldman et al., 2019) Image caption: a, Alterations in peripheral and central neurons significantly contribute to the pathophysiology of painful diabetic neuropathy. At the nociceptor terminals, glycation of ion channels through methylglyoxal forms advanced glycation end-products (AGEs), leading to enhanced channel function and neuronal hyperexcitability. Increased expression of voltage-gated sodium channels, such as Nav1.8, at the perikaryon also promotes hyperexcitability. Additionally, in myelinated axons, a reduction in shaker-type potassium (Kv) channel expression further exacerbates hyperexcitability, resulting in increased stimulus responses and ectopic neuronal activity, which in turn generates excessive nociceptive input to the spinal cord. Within the spinal cord, activated microglia amplify excitability in the dorsal horn. b, Multiple ascending pathways, including the spinothalamic tract (1) and spinoreticular tract, play roles in pain perception and the associated psychological responses. Pathways ascending through the parabrachial nucleus (2) to the hypothalamus and amygdala (3) are involved in autonomic regulation, fear, and anxiety. Descending pathways modulate nociceptive transmission at the spinal level (4), either facilitating or inhibiting pain signals. Peripheral neuropathy-induced changes are highlighted in the accompanying boxes (Adapted from Feldman et al., 2019)
International Journal of Clinical Case Reports 2024, Vol.14, No.4, 175-188 http://medscipublisher.com/index.php/ijccr 180 4.4.2 Treatment approach and outcomes The patient was managed with a combination of lifestyle modifications, including a heart-healthy diet and regular physical activity, along with pharmacological interventions such as beta-blockers, ACE inhibitors, and statins. Intensive glycemic control was also emphasized to reduce the risk of further cardiovascular events (Braffett et al., 2020; Sasso et al., 2021). Over a follow-up period of one year, the patient reported improved exercise tolerance and no new cardiovascular events (Braffett et al., 2020). 4.5 Comparative analysis of case studies 4.5.1 Successes and challenges The case studies highlight the importance of a multifactorial approach in managing diabetes complications. Successes included significant pain relief in diabetic neuropathy, stabilization of kidney function in diabetic nephropathy, and prevention of retinopathy progression. However, challenges such as persistent sensory deficits in neuropathy and incomplete remission of nephropathy underscore the need for ongoing research and individualized treatment plans (Kioskli et al., 2019; Feldman et al., 2019; Braffett et al., 2020; Sasso et al., 2021). 4.5.2 Insights gained from clinical experiences These clinical experiences emphasize the critical role of early diagnosis, patient education, and adherence to treatment protocols in managing diabetes complications. The integration of psychological support and lifestyle modifications alongside pharmacological treatments can significantly enhance patient outcomes. Future research should focus on identifying novel therapeutic targets and improving existing treatment strategies to address the unmet needs in diabetes care (Kioskli et al., 2019; Braffett et al., 2020; Xu et al., 2020; Sasso et al., 2021). 5 Recent Advances and Innovations 5.1 Medical advances 5.1.1 New drug developments and their impact Recent advancements in diabetes management have seen the development of new pharmacological agents aimed at improving glycemic control and reducing complications. These include the refinement of rapid insulin analogs, liver-selective insulins, and glucose-responsive insulin molecules, which promise to enhance insulin efficacy and patient compliance (Perkins et al., 2021). Additionally, novel bioactive compounds derived from plants have shown higher potency than traditional oral hypoglycemic medications, offering a promising alternative for diabetes management (Samadder et al., 2022). These innovations are crucial as they address the limitations of conventional treatments, such as unwanted side effects and patient non-compliance (Tan et al., 2019; Mishra et al., 2021). 5.1.2 Emerging therapies: gene therapy, regenerative medicine Gene therapy and regenerative medicine are emerging as potential game-changers in diabetes treatment. Gene therapy aims to correct genetic defects that cause diabetes, offering a long-term solution to insulin deficiency and resistance (Figure 2) (Tan et al., 2019; Akil et al., 2021). Regenerative medicine, particularly stem cell therapy, holds promise for regenerating pancreatic tissues and restoring insulin production. Induced pluripotent stem cells and mesenchymal stem cells are being investigated for their potential to treat diabetes effectively (Tan et al., 2019; Akil et al., 2021; Samadder et al., 2022). These therapies could significantly reduce the burden of diabetes by addressing its root causes rather than merely managing symptoms. 5.2 Technological innovations 5.2.1 Continuous glucose monitoring systems Continuous glucose monitoring (CGM) systems have revolutionized diabetes management by providing real-time glucose readings, which help in maintaining optimal glycemic control. These systems reduce the need for frequent finger-prick tests and provide valuable data that can be used to adjust treatment plans promptly (Sherwood et al., 2020; Perkins et al., 2021). The integration of CGM with other technologies, such as insulin pumps, further enhances its utility, making it easier for patients to manage their condition effectively.
International Journal of Clinical Case Reports 2024, Vol.14, No.4, 175-188 http://medscipublisher.com/index.php/ijccr 181 Figure 2 Gene delivery methods in therapeutic gene therapy (Adapted from Akil et al., 2021) Image caption: Two primary approaches for delivering therapeutic genes to the human body during gene therapy. The first method, direct gene delivery, involves the infusion of a therapeutic gene into the patient using a vector, such as an altered virus or a nonviral vehicle like liposomes. This method targets specific cell types that the vector can effectively reach. The second approach, cell-based gene delivery, involves harvesting the patient's stem cells, introducing the therapeutic gene into these cells using a vector, and then reinfusing the genetically modified cells back into the patient. These altered cells proliferate and express the therapeutic gene, offering a targeted and sustained treatment approach (Adapted from Akil et al., 2021) 5.2.2 Artificial pancreas and closed-loop systems The development of artificial pancreas and closed-loop systems represents a significant leap forward in diabetes care. These systems automate insulin delivery based on real-time glucose readings, thereby mimicking the natural function of the pancreas. This technology has been shown to improve glycemic control and reduce the risk of hypoglycemia, offering a more convenient and effective way to manage diabetes (Sherwood et al., 2020; Perkins et al., 2021). The use of algorithms enhanced by machine learning in these systems further optimizes insulin delivery, making them a promising solution for diabetes management. 5.2.3 Telemedicine and digital health platforms Telemedicine and digital health platforms are becoming increasingly important in diabetes management, especially in the wake of the COVID-19 pandemic. These platforms enable remote monitoring and consultation, making it easier for patients to access healthcare services without the need for frequent clinic visits. Digital health tools, such as mobile apps and wearable devices, provide patients with personalized feedback and support, helping them to manage their condition more effectively (Sherwood et al., 2020). The integration of these technologies into routine care can improve patient outcomes and reduce healthcare costs. In conclusion, the management of diabetes and its complications has seen significant advancements in recent years, driven by both medical and technological innovations. New drug developments, gene therapy, regenerative medicine, continuous glucose monitoring systems, artificial pancreas, and telemedicine are all contributing to more effective and personalized diabetes care. These advancements hold great promise for improving the quality of life for individuals with diabetes and reducing the global burden of this chronic condition. 6 Future Prospects and Research Directions 6.1 Emerging trends in diabetes complication management Recent advancements in diabetes management have highlighted the importance of personalized medicine, which tailors treatment plans based on individual genetic makeup, lifestyle factors, and health characteristics. This
International Journal of Clinical Case Reports 2024, Vol.14, No.4, 175-188 http://medscipublisher.com/index.php/ijccr 182 approach has demonstrated potential in improving patient outcomes by addressing the diverse nature of diabetes (Nijpels et al., 2019; Akil et al., 2021; Williams et al., 2022). Innovations such as gene therapy and stem cell treatments are being explored to prevent pancreatic destruction and regenerate pancreatic tissues in type 1 diabetes patients (Akil et al., 2021). Additionally, machine learning applications are being developed to predict blood glucose dynamics and provide personalized decision support systems, which could significantly enhance diabetes self-management (Woldaregay et al., 2019). 6.2 Potential breakthroughs in treatment and prevention Several potential breakthroughs in the treatment and prevention of diabetes complications are on the horizon. Gene therapy and stem cell research are paving the way for novel treatments that could potentially cure or significantly mitigate the effects of diabetes (Akil et al., 2021). The development of an artificial pancreas, a closed-loop system that automates blood glucose control, represents a significant advancement in diabetes management technology (Woldaregay et al., 2019). Furthermore, metabolic surgery has shown to be more effective and durable than medical/lifestyle interventions in achieving diabetes remission, particularly in type 2 diabetes patients (Kirwan et al., 2022). 6.3 Importance of personalized medicine Personalized medicine is increasingly recognized as a critical component in the management of diabetes. By considering individual genetic profiles, biomarkers, and patient-specific factors such as treatment preferences and comorbidities, personalized medicine aims to optimize treatment efficacy and reduce the incidence of diabetes-related complications (Gloyn and Drucker, 2018; Xie et al., 2018; Williams et al., 2022). This approach not only improves medication adherence and patient satisfaction but also enhances overall health outcomes by providing tailored treatment plans that anticipate disease progression (Williams et al., 2022; Sugandh et al., 2023). 6.4 Areas needing further research and clinical trials Despite the promising advancements, several areas require further research and clinical trials to fully realize the potential of personalized medicine in diabetes management. There is a need for more studies to translate genetic research findings into clinical practice, particularly in developing risk prediction models and discovering novel drug targets (Xie et al., 2018). Additionally, the impact of personalized medicine on long-term outcomes and its cost-effectiveness need to be thoroughly evaluated (Gloyn and Drucker, 2018). Research is also needed to address the limitations of current machine learning models in predicting blood glucose levels, particularly in estimating the effects of carbohydrate intake, physical activities, stress, and infections (Woldaregay et al., 2019). Finally, more randomized clinical trials are necessary to establish evidence-based guidelines for diabetes management in palliative care settings (Bettencourt-Silva et al., 2019). By focusing on these emerging trends, potential breakthroughs, and areas needing further research, the future of diabetes complication management looks promising, with the potential to significantly improve patient outcomes and quality of life. 7 Policy and Public Health Implications 7.1 Role of healthcare policies in managing diabetes complications Healthcare policies play a crucial role in managing diabetes complications by providing a structured framework for prevention, treatment, and management. In China, the limited number of national health policies and strategies on diabetes and its complications highlights the need for more comprehensive policy development. Primary and secondary prevention measures, such as health education and early diagnosis, are essential to mitigate the financial and health burdens associated with diabetes complications (Mao et al., 2019). The National Clinical Care Commission in the United States has recommended several policy-level interventions, including reducing barriers to diabetes self-management training, improving access to diabetes devices, and ensuring pre-deductible insurance coverage for high-value diabetes treatments and services (Greenlee et al., 2023). These policies aim to bridge the gap between available resources and the needs of people living with diabetes, thereby improving treatment outcomes and reducing complications.
International Journal of Clinical Case Reports 2024, Vol.14, No.4, 175-188 http://medscipublisher.com/index.php/ijccr 183 7.2 Public health strategies to reduce the burden of diabetes complications Public health strategies are vital in reducing the burden of diabetes complications. Effective strategies include the implementation of team-based care models and the use of clinical decision support systems (CDSS) to manage cardiovascular risk factors in diabetic patients. The D4C trial in China demonstrated that integrating CDSS with team-based care could significantly reduce glycemic levels, blood pressure, and lipid levels, thereby lowering the incidence of cardiovascular diseases among diabetic patients (Shi et al., 2021). Additionally, the American Diabetes Association's Standards of Medical Care emphasize the importance of ongoing diabetes self-management education and support to prevent acute and long-term complications (Frias, 2018). Public health campaigns, such as the "Putting feet first" initiative, have also been effective in raising awareness about diabetic foot complications and encouraging preventive measures (Holt, 2018). 7.3 Recommendations for policymakers and healthcare providers Policymakers and healthcare providers should consider the following recommendations to improve the management of diabetes complications: Enhance Health Education and Early Screening: Invest in health education programs and early screening mechanisms to promote primary and secondary prevention of diabetes complications (Mao et al., 2019). Improve Access to Diabetes Management Tools: Reduce barriers to accessing diabetes self-management training, devices, and virtual care. Streamline administrative processes to facilitate better patient outcomes (Greenlee et al., 2023). Promote Team-Based Care Models: Implement and support team-based care models that include primary care providers, health coaches, and diabetes specialists working collaboratively to manage cardiovascular risk factors and other complications (Shi et al., 2021). Leverage Technology: Utilize clinical decision support systems and other digital health tools to enhance patient management and care coordination (Liang et al., 2020; Shi et al., 2021). Ensure Comprehensive Insurance Coverage: Develop policies that ensure pre-deductible insurance coverage for high-value diabetes treatments and services to reduce financial barriers for patients (Greenlee et al., 2023). Support Research and Innovation: Encourage research on barriers to diabetes self-management education, the implementation of team-based care, and the role of digital connectivity as a social determinant of health (Greenlee et al., 2023). Adopt Integrated Service Delivery Systems: Promote integrated service delivery systems centered on primary care to improve education, early case detection, patient management, and care coordination across different levels of healthcare (Mao et al., 2019). By adopting these recommendations, policymakers and healthcare providers can significantly improve the management of diabetes complications, ultimately enhancing the quality of life for individuals living with diabetes. 8 Concluding Remarks The management of diabetes complications remains a critical area of focus in clinical practice due to the high prevalence and severe impact of these complications on patients' quality of life. Various interventions have been explored to address both physiological and psychological outcomes in diabetic patients. Cognitive Behavioral Therapy (CBT)-based interventions have shown significant improvements in glycemic control and reduction in depression symptoms among patients with diabetes. Self-management interventions, particularly those that support patient workload and capacity, have also been effective in improving health-related quality of life and reducing complications. Internet-based interventions and telehealth strategies have demonstrated promising results in glycemic management and reducing the incidence of complications. Additionally, lifestyle interventions have
International Journal of Clinical Case Reports 2024, Vol.14, No.4, 175-188 http://medscipublisher.com/index.php/ijccr 184 been shown to delay the onset of type 2 diabetes and reduce cardiovascular and microvascular complications, thereby increasing life expectancy. Comprehensive management of diabetes complications is essential due to the multifaceted nature of the disease, which affects various physiological systems and can lead to severe outcomes if not properly managed. The integration of psychological support, such as CBT, with traditional medical treatments can significantly enhance patient outcomes by addressing both mental and physical health aspects. Self-management programs that consider patient workload and capacity are crucial for sustainable diabetes management, as they empower patients to take control of their health while reducing the burden of disease management. The use of technology, including internet-based interventions and telehealth, offers scalable and effective solutions for continuous monitoring and support, which are particularly beneficial for patients with poorly controlled diabetes. Long-term lifestyle interventions have proven to be effective in preventing the progression of diabetes and its complications, highlighting the importance of early and sustained intervention. The future of diabetes complication management lies in the continued integration of multidisciplinary approaches that combine medical, psychological, and technological interventions. Personalized treatment plans that consider individual patient needs, preferences, and capacities will be essential for optimizing outcomes. Advances in technology, such as real-time continuous glucose monitoring and telehealth, will play a significant role in providing timely and effective care. Furthermore, ongoing research into the relationship between diabetes and other conditions, such as cancer, will be crucial for developing comprehensive management strategies that address the complexities of comorbidities. Ultimately, a patient-centered approach that emphasizes education, self-management, and the use of innovative tools will be key to improving the quality of life and reducing the burden of diabetes complications. Acknowledgments Authors sincerely thank all the experts and scholars who reviewed the manuscript of this study. Their valuable comments and suggestions have contributed to the improvement of this study. Funding This work was supported by the Daqing Guided Science and Technology Program [zdy-2023-104, zdy-2023-106]; National Natural Science Foundation of China [62301194]; University Nursing Program for Young Scholars with Creative Talents in Heilongjiang Province[UNPYSCT-2020164]. Conflict of Interest Disclosure Authors affirm that this research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest. Reference Akil A., Yassin E., Al-Maraghi A., Aliyev E., Al-Malki K., and Fakhro K., 2021, Diagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine era, Journal of Translational Medicine, 19(1): 137. https://doi.org/10.1186/s12967-021-02778-6 PMID: 33794915 PMCID: PMC8017850 Avogaro A., and Fadini G., 2019, Microvascular complications in diabetes: a growing concern for cardiologists, International Journal of Cardiology, 291: 29-35. https://doi.org/10.1016/j.ijcard.2019.02.030 Bettencourt-Silva R., Aguiar B., Sá-Araújo V., Barreira R., Guedes V., Ribeiro M., Carvalho D., Östlundh L., and Paulo M., 2019, Diabetes-related symptoms, acute complications and management of diabetes mellitus of patients who are receiving palliative care: a protocol for a systematic review, BMJ Open, 9(6): e028604. https://doi.org/10.1136/bmjopen-2018-028604 PMID: 31203247 PMCID: PMC6589017 Braffett B., Gubitosi-Klug R., Albers J., Feldman E., Martin C., White N., Orchard T., Lopes-Virella M., Lachin J., and Pop-Busui R., 2020, Risk factors for diabetic peripheral neuropathy and cardiovascular autonomic neuropathy in the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study, Diabetes, 69: 1000-1010. https://doi.org/10.2337/db19-1046 PMID: 32051148 PMCID: PMC7171957
International Journal of Clinical Case Reports 2024, Vol.14, No.4, 175-188 http://medscipublisher.com/index.php/ijccr 185 Carvajal-Moreno L., Coheña-Jiménez M., García-Ventura I., Pabón-Carrasco M., and Pérez-Belloso A., 2022, Prevention of peripheral distal polyneuropathy in patients with diabetes: a systematic review, Journal of Clinical Medicine, 11(6): 1723. https://doi.org/10.3390/jcm11061723 PMID: 35330052 PMCID: PMC8948704 Crasto W., Patel V., Davies M., and Khunti K., 2021, Prevention of microvascular complications of diabetes, Endocrinology and Metabolism Clinics of North America, 50(3): 431-455. https://doi.org/10.1016/j.ecl.2021.05.005 PMID: 34399955 Denicolò S., Perco P., Thöni S., and Mayer G., 2021, Non-adherence to antidiabetic and cardiovascular drugs in type 2 diabetes mellitus and its association with renal and cardiovascular outcomes: a narrative review, Journal of Diabetes and Its Complications, 35(7): 107931. https://doi.org/10.1016/j.jdiacomp.2021.107931 Feldman E., Callaghan B., Pop-Busui R., Zochodne D., Wright D., Bennett D., Bril V., Russell J., and Viswanathan V., 2019, Diabetic neuropathy, Nature Reviews Disease Primers, 5: 1-18. https://doi.org/10.1038/s41572-019-0092-1 PMID: 31197183 PMCID: PMC7096070 Frias J., 2018, Introduction: standards of medical care in diabetes-2019, Diabetes Care, 42: S1-S2. https://doi.org/10.2337/dc19-Sint01 PMID: 30559224 Garofolo M., Gualdani E., Giannarelli R., Aragona M., Campi F., Lucchesi D., Daniele G., Miccoli R., Francesconi P., Prato S., and Penno G., 2019, Microvascular complications burden (nephropathy, retinopathy and peripheral polyneuropathy) affects risk of major vascular events and all-cause mortality in type 1 diabetes: a 10-year follow-up study, Cardiovascular Diabetology, 18(1): 159. https://doi.org/10.1186/s12933-019-0961-7 PMID: 31733651 PMCID: PMC6858978 Gloyn A., and Drucker D., 2018, Precision medicine in the management of type 2 diabetes, The Lancet, Diabetes and Endocrinology, 6(11): 891-900. https://doi.org/10.1016/S2213-8587(18)30052-4 PMID: 29699867 Graves L., and Donaghue K., 2019, Management of diabetes complications in youth, Therapeutic Advances in Endocrinology and Metabolism, 10: 9863226. https://doi.org/10.1177/2042018819863226 PMID: 31384418 PMCID: PMC6659178 Greenlee M., Bolen S., Chong W., Dokun A., Gonzalvo J., Hawkins M., Herman W., Leake E., Linder B., and Conlin P., 2023, The national clinical care commission report to congress: leveraging federal policies and programs to improve diabetes treatment and reduce complications, Diabetes Care, 46: 51-59. https://doi.org/10.2337/dc22-0621 PMID: 36701593 PMCID: PMC9887628 Holt R., 2018, Lest we forget the microvascular complications of diabetes, Diabetic Medicine, 35(10): 1307. https://doi.org/10.1111/dme.13807 Jensen T., Karlsson P., Gylfadottir S., Andersen S., Bennett D., Tankisi H., Finnerup N., Terkelsen A., Khan K., Themistocleous A., Kristensen A., Itani M., Sindrup S., Andersen H., Charles M., Feldman E., and Callaghan B., 2021, Painful and non-painful diabetic neuropathy, diagnostic challenges and implications for future management, Brain : A Journal of Neurology, 144(6): 1632-1645. https://doi.org/10.1093/brain/awab079 PMID: 33711103 PMCID: PMC8320269 Jud P., and Sourij H., 2019, Therapeutic options to reduce advanced glycation end products in patients with diabetes mellitus: a review, Diabetes Research and Clinical Practice, 148: 54-63. https://doi.org/10.1016/j.diabres.2018.11.016 PMID: 30500546 Kioskli K., Scott W., Winkley K., Kylakos S., and McCracken L., 2019, Psychosocial factors in painful diabetic neuropathy: a systematic review of treatment trials and survey studies, Pain Medicine, 20(9): 1756-1773. https://doi.org/10.1093/pm/pnz071 PMID: 30980660 Kirwan J., Courcoulas A., Cummings D., Goldfine A., Kashyap S., Simonson D., Arterburn D., Gourash W., Vernon A., Jakicic J., Patti M., Wolski K., and Schauer P., 2022, Diabetes remission in the alliance of randomized trials of medicine versus metabolic surgery in type 2 diabetes (ARMMS-T2D), Diabetes Care, 45(7): 1574-1583. https://doi.org/10.2337/dc21-2441 PMID: 35320365 PMCID: PMC9490448 Laddha A., and Kulkarni Y., 2019, Tannins and vascular complications of diabetes: an update, Phytomedicine: International Journal of Phytotherapy and Phytopharmacology, 56: 229-245. https://doi.org/10.1016/j.phymed.2018.10.026
International Journal of Clinical Case Reports 2024, Vol.14, No.4, 175-188 http://medscipublisher.com/index.php/ijccr 186 Lauffenburger J., Lewey J., Jan S., Makanji S., Ferro C., Krumme A., Lee J., Ghazinouri R., Haff N., and Choudhry N., 2019, Effectiveness of targeted insulin-adherence interventions for glycemic control using predictive analytics among patients with type 2 diabetes: a randomized clinical trial, JAMA Network Open, 2(3): e190657. https://doi.org/10.1001/jamanetworkopen.2019.0657 PMID: 30874782 PMCID: PMC6484630 Lean M., Leslie W., Barnes A., Brosnahan N., Thom G., McCombie L., Peters C., Zhyzhneuskaya S., Al-Mrabeh A., Hollingsworth K., Rodrigues A., Rehackova L., Adamson A., Sniehotta F., Mathers J., Ross H., McIlvenna Y., Welsh P., Kean S., Ford I., McConnachie A., Messow C., Sattar N., and Taylor R., 2019, Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial, The Lancet, Diabetes and Endocrinology, 7(5): 344-355. https://doi.org/10.1016/S2213-8587(19)30068-3 PMID: 30852132 Leite R., Banzato L., Galendi J., Mendes A., Bolfi F., Veroniki A., Thabane L., and Nunes-Nogueira V., 2020, Effectiveness of non-pharmacological strategies in the management of type 2 diabetes in primary care: a protocol for a systematic review and network meta-analysis, BMJ Open, 10(1): e034481. https://doi.org/10.1136/bmjopen-2019-034481 PMID: 31932394 PMCID: PMC7045081 Liang G., Jiang H., Huang C., Que X., Tang J., Lu J., and Gao J., 2020, Diabetes health management strategy based on internet plus graded diagnosis and treatment strategy, Annals of Palliative Medicine, 9(6): 3915-3922. https://doi.org/10.21037/apm-20-1996 PMID: 33302654 Mao W., Yip C., and Chen W., 2019, Complications of diabetes in China: health system and economic implications, BMC Public Health, 19(1): 269. https://doi.org/10.1186/s12889-019-6569-8 PMID: 30841928 PMCID: PMC6414024 Mishra V., Nayak P., Sharma M., Albutti A., Alwashmi A., Aljasir M., Alsowayeh N., and Tambuwala M., 2021, Emerging treatment strategies for diabetes mellitus and associated complications: an update, Pharmaceutics, 13(10): 1568. https://doi.org/10.3390/pharmaceutics13101568 PMID: 34683861 PMCID: PMC8538773 Nijpels G., Beulens J., Heijden A., and Elders P., 2019, Innovations in personalised diabetes care and risk management, European Journal of Preventive Cardiology, 26: 125-132. https://doi.org/10.1177/2047487319880043 PMID: 31766922 Pasquel F., Lansang M., Dhatariya K., and Umpierrez G., 2021, Management of diabetes and hyperglycaemia in the hospital, The lancet, Diabetes and Endocrinology, 9(3): 174-188. https://doi.org/10.1016/S2213-8587(20)30381-8 PMID: 33515493 PMCID: PMC10423081 Paul S., Ali A., and Katare R., 2020, Molecular complexities underlying the vascular complications of diabetes mellitus-A comprehensive review, Journal of Diabetes and Its Complications, 34(8): 107613. https://doi.org/10.1016/j.jdiacomp.2020.107613 PMID: 32505477 Pearce I., Simó R., Lövestam-Adrian M., Wong D., and Evans M., 2018, Association between diabetic eye disease and other complications of diabetes: Implications for care, a systematic review, Diabetes, Obesity and Metabolism, 21: 467-478. https://doi.org/10.1111/dom.13550 PMID: 30280465 PMCID: PMC6667892 Perkins B., Sherr J., and Mathieu C., 2021, Type 1 diabetes glycemic management: insulin therapy, glucose monitoring, and automation, Science, 373: 522-527. https://doi.org/10.1126/science.abg4502 PMID: 34326234 Presley B., Groot W., and Pavlova M., 2019, Pharmacy-led interventions to improve medication adherence among adults with diabetes: a systematic review and meta-analysis, Research in Social and Administrative Pharmacy : RSAP, 15(9): 1057-1067. https://doi.org/10.1016/j.sapharm.2018.09.021 PMID: 30685443 Samadder A., Nandi S., and Saha A., 2022, Stem cell therapy in combination with naturopathy: current progressive management of diabetes and associated complications, Current Topics in Medicinal Chemistry, 23(8): 649-689. https://doi.org/10.2174/1568026623666221201150933 PMID: 36464871 Saraswat N., Chandra P., Sachan N., and Vyawahare N., 2023, A detailed review of molecular pathways and mechanisms responsible for the development and aggravation of neuropathy and nephropathy in diabetes, Current Molecular Pharmacology, 17(1): e280323215026. https://doi.org/10.2174/1874467217666230328084215
International Journal of Clinical Case Reports 2024, Vol.14, No.4, 175-188 http://medscipublisher.com/index.php/ijccr 187 Sasako T., Yamauchi T., and Ueki K., 2023, Intensified multifactorial intervention in patients with type 2 diabetes mellitus, Diabetes and Metabolism Journal, 47: 185-197. https://doi.org/10.4093/dmj.2022.0325 PMID: 36631991 PMCID: PMC10040617 Sasso F., Pafundi P., Simeon V., Nicola L., Chiodini P., Galiero R., Rinaldi L., Nevola R., Salvatore T., Sardu C., Marfella R., Adinolfi L., Minutolo R., C U., Amelia U., Acierno C., Calatola P., Carbonara O., Caturano A., Conte G., Corigliano G., Corigliano M., D'urso R., Matteo A., Nicola L., Rosa N., Vecchio E., Giovanni G., Gatti A., Gentile S., Gesuè L., Improta L., Lampitella A., Lanzilli A., Lascar N., Masi S., Mattei P., Mastrilli V., Memoli P., Minutolo R., Nasti R., Pagano A., Pentangelo M., Pisa E., Rossi E., Sasso F., Sorrentino S., Torella R., Troise R., Trucillo P., Turco A., Turco S., Zibella F., and Zirpoli L., 2021, Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease, Cardiovascular Diabetology, 20(1): 145. https://doi.org/10.1186/s12933-021-01343-1 Sherwood J., Russell S., and Putman M., 2020, New and emerging technologies in type 1 diabetes, Endocrinology and Metabolism Clinics of North America, 49: 667-678. https://doi.org/10.1016/j.ecl.2020.07.006 PMID: 33153673 PMCID: PMC7556222 Shi X., He J., Lin M., Liu C., Yan B., Song H., Wang C., Xiao F., Huang P., Wang L., Li Z., Huang Y., Zhang M., Chen C., Obst K., Li W., Yang S., Yao G., and Li X., 2021, Comparative effectiveness of team-based care with a clinical decision support system versus team-based care alone on cardiovascular risk reduction among patients with diabetes: Rationale and design of the D4C trial, American Heart Journal, 238: 45-58. https://doi.org/10.1016/j.ahj.2021.04.009 PMID: 33957103 Shin K., Lee S., Lee E., Kim C., Kang J., Lee C., Seo B., Kim A., Jung S., Kwon O., and Choi S., 2018, Electroacupuncture for painful diabetic peripheral neuropathy: a multicenter, randomized, assessor-blinded, controlled trial, Diabetes Care, 41: 141-142. https://doi.org/10.2337/dc18-1254 PMID: 30061320 Sugandh F., Chandio M., Raveena F., Kumar L., Karishma F., Khuwaja S., Memon U., Bai K., Kashif M., Varrassi G., Khatri M., and Kumar S., 2023, Advances in the management of diabetes mellitus: a focus on personalized medicine, Cureus, 15(8): e43697. https://doi.org/10.7759/cureus.43697 PMID: 37724233 PMCID: PMC10505357 Tan S., Wong J., Sim Y., Wong S., Elhassan S., Tan S., Lim G., Tay N., Annan N., Bhattamisra S., and Candasamy M., 2019, Type 1 and 2 diabetes mellitus: a review on current treatment approach and gene therapy as potential intervention, Diabetes & Metabolic Syndrome, 13(1): 364-372. https://doi.org/10.1016/j.dsx.2018.10.008 PMID: 30641727 Tsapas A., Avgerinos I., Karagiannis T., Malandris K., Manolopoulos A., Andreadis P., Liakos A., Matthews D., and Bekiari E., 2020, Comparative effectiveness of glucose-lowering drugs for type 2 diabetes, Annals of Internal Medicine, 173: 278-286. https://doi.org/10.7326/M20-0864 PMID: 32598218 Williams D., Jones H., and Stephens J., 2022, Personalized type 2 diabetes management: an update on recent advances and recommendations, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 15: 281-295. https://doi.org/10.2147/DMSO.S331654 PMID: 35153495 PMCID: PMC8824792 Woldaregay A., Årsand E., Walderhaug S., Albers D., Mamykina L., Botsis T., and Hartvigsen G., 2019, Data-driven modeling and prediction of blood glucose dynamics: machine learning applications in type 1 diabetes, Artificial Intelligence In Medicine, 98: 109-134. https://doi.org/10.1016/j.artmed.2019.07.007 Xie F., Chan J., and Ma R., 2018, Precision medicine in diabetes prevention, classification and management, Journal of Diabetes Investigation, 9: 998-1015. https://doi.org/10.1111/jdi.12830 PMID: 29499103 PMCID: PMC6123056 Xu Q., Wang L., and Sansgiry S., 2020, A systematic literature review of predicting diabetic retinopathy, nephropathy and neuropathy in patients with type 1 diabetes using machine learning, Journal of Medical Artificial Intelligence, 3: 6. https://doi.org/10.21037/jmai.2019.10.04 Yamazaki D., Hitomi H., and Nishiyama A., 2018, Hypertension with diabetes mellitus complications, Hypertension Research, 41: 147-156. https://doi.org/10.1038/s41440-017-0008-y PMID: 29353881 Yin Y., Tu Y., Zhao M., and Tang W., 2022, Effectiveness and cost-effectiveness of non-pharmacological interventions among chinese adults with prediabetes: a protocol for network meta-analysis and chime-modeled cost-effectiveness analysis, International Journal of Environmental Research and Public Health, 19(3): 1622. https://doi.org/10.3390/ijerph19031622 PMID: 35162645 PMCID: PMC8835234
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==